Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3

Topical Insulin - Utility and Results in Neurotrophic Keratopathy in Stages 2 and 3

Sponsors

Lead Sponsor: Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

Source Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.
Brief Summary

Purpose: To evaluate the clinical outcome of patients with refractory Neurotrophic Keratopathy (NK) in stages 2 and 3 treated with topical insulin. Methods: A retrospective, observational analysis of eyes with NK in stages 2 and 3 refractory to standard medical and/or surgical treatment which were treated with topical insulin. Topical insulin (1 unit per mL) was applied 4 times a day; treatment was continued until persistent epithelial defect (PED) or ulcer resolved and then tapered accordingly. The primary outcome of the study was the complete resolution of the PED or ulcer. Best-corrected visual acuity (BCVA), days until complete resolution as well as anterior segment photographs were obtained.

Detailed Description

Study type Retrospective, observational, single-center study at the Department of Ophthalmology of Centro Hospitalar Vila Nova de Gaia e Espinho, EPE. Data was obtained from patients' medical records and anterior segment photographs from October 1, 2018 to November 1, 2020. Each participant and/or relative was given a detailed explanation and a written informed consent regarding possible alternatives, risks and benefits of off-label use of topical insulin drops. This study was approved by the board of Centro Hospitalar de Vila Nova de Gaia e Espinho (UIEC-2020-981914339595fa024c567ec5). This study complied with the tenets of the Declaration of Helsinki. Patient selection Patients included in this study were provided from the Cornea department of the Ophthalmology center in Centro Hospitalar de Vila Nova de Gaia e Espinho. Every patient included had an established diagnosis of NK (ICD10: H16.2) in stages 2 or 3 that was refractory to standard medical and/or surgical treatment and underwent treatment with topical insulin. All patients underwent complete ophthalmological exam including best-corrected visual acuity, slit-lamp examination, corneal sensitivity in the center and four quadrants of the cornea and fundoscopic evaluation. NK was graded based on slit-lamp and fluorescein stain findings - stage 2: epithelial defect (with or without a rim of loose epithelium) without stromal ulceration; stage 3: corneal ulceration and/or stromal lysis. Topical insulin preparation and administration Topical insulin drops were prepared by diluting 1 unit of fast-acting insulin per 1 mL of an artificial tear with a propylene glycol base. Drops were preserved at low temperature (2ºC) and were applied four times a day. A therapeutic corneal CL was placed in every patient and fluoroquinolone drops were applied to prevent possible CL side-effects. Treatment was continued until NK PED or Ulcer resolved and tapered accordingly. Patients would discontinue topical insulin if the condition did not improve within 30 days or worsen. Follow-up was ensured on the 3rd,5th, and 7th day and then individualized during the full-extent of treatment. Anterior segment photos were taken on each visit.

Overall Status Completed
Start Date 2018-10-01
Completion Date 2020-11-01
Primary Completion Date 2020-11-01
Study Type Observational
Primary Outcome
Measure Time Frame
Days until closure of the corneal wound Time until complete resolution of corneal wound, assessed up to 8 weeks
Secondary Outcome
Measure Time Frame
Best-corrected Visual Acuity improvement Before and after treatment completion, assessed up to 8 weeks
Enrollment 20
Condition
Intervention

Intervention Type: Drug

Intervention Name: Topical Insulin

Description: Patients were administered eyedrops enriched with insulin

Eligibility

Sampling Method:

Non-Probability Sample

Criteria:

Inclusion criteria included: • Eyes with established diagnosis of NK in stages 2 or 3 refractory to standard treatment* that underwent topical insulin treatment. The diagnosis of NK was based on the following criteria: 1. Decreased or absence of corneal sensation; AND 2. Corneal injury [PED and/or corneal ulcer] refractory to standard treatment*; AND 3. Clinical history of conditions related to trigeminal innervation impairment; - Standard treatment - lubrication with artificial tears, topical and/or oral antibiotics, topical and/or oral steroids, antiviral drugs, punctal plugs, therapeutic CL, amniotic membrane surgery and temporary tarsorrhaphy.´ We excluded every patient with corneal ulcer and signs of infection.

Gender:

All

Minimum Age:

N/A

Maximum Age:

N/A

Healthy Volunteers:

No

Location
Facility: Centro Hospitalar Vila Nova de Gaia e Espinho
Location Countries

Portugal

Verification Date

2021-04-01

Responsible Party

Type: Principal Investigator

Investigator Affiliation: Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E.

Investigator Full Name: Dr. Ricardo Machado Soares, MD

Investigator Title: Principal Investigator

Has Expanded Access No
Condition Browse
Study Design Info

Observational Model: Case-Only

Time Perspective: Retrospective

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Research News